David Einhorn's NUVB Position Overview
David Einhorn (via Dme Capital Management, Lp) currently holds 34,995 shares of Nuvation Bio Inc. (NUVB) worth $313,555, representing 0.01% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 20 quarters.
Based on 13F filings, David Einhorn has maintained a strategic position in NUVB, demonstrating sustained confidence in this investment. Largest reduction occurred in Q2 2021, reducing 115,005 shares.
Analysis based on 13F filings available since 2013 Q2
David Einhorn's Nuvation Bio (NUVB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nuvation Bio (NUVB) Trades by David Einhorn
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2024 | +34,996 | Add 0.00% | 34,995 | $3.64 |
| Q2 2021 | -115,005 | Reduce 76.67% | 34,995 | $9.32 |
| Q1 2021 | +150,000 | New Buy | 150,000 | $10.45 |
David Einhorn's Nuvation Bio Investment FAQs
David Einhorn first purchased Nuvation Bio Inc. (NUVB) in Q1 2021, acquiring 150,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn has held Nuvation Bio Inc. (NUVB) for 20 quarters since Q1 2021.
David Einhorn's largest addition to Nuvation Bio Inc. (NUVB) was in Q1 2021, adding 150,000 shares worth $1.57 M.
According to the latest 13F filing for Q4 2025, David Einhorn's firm, Dme Capital Management, Lp, owns 34,995 shares of Nuvation Bio Inc. (NUVB), valued at approximately $313,555.
As of the Q4 2025 filing, Nuvation Bio Inc. (NUVB) represents approximately 0.01% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings.
David Einhorn's peak holding in Nuvation Bio Inc. (NUVB) was 150,000 shares, as reported at the end of Q1 2021.